BCL2L11 and neoplasm: Although MEK inhibition may blunt the ability of tumor cells to respond to a variety of pro-apoptotic stimuli, a potential stumbling block lies in the finding that elevated levels of BCL-2 appear to have the capacity to counteract the increases in BIM brought about by MEK inhibition, thus inhibiting the pro-apoptotic function of BIM [24].